Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Recombinant Protein / Other Proteins

Recombinant HIV1 gp120/SU Protein, C-His

Catalog #:   EVV07801 Specific References (92) DATASHEET
Applications: ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Expression system: Mammalian Cells
Accession: Q9YUL5
Protein length: Ala29-Arg513
Overview

Catalog No.

EVV07801

Expression system

Mammalian Cells

Species

Human immunodeficiency virus type 1 (HIV-1)

Protein length

Ala29-Arg513

Predicted molecular weight

57.06 kDa

Nature

Recombinant

Endotoxin level

Please contact with the lab for this information.

Purity

>90% as determined by SDS-PAGE.

Accession

Q9YUL5

Applications

ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress

Form

Lyophilized

Storage buffer

Lyophilized from a solution in PBS pH 7.4, 1mM EDTA, 4% Trehalose, 1% Mannitol.

Reconstitution

Reconstitute in sterile water for a stock solution.A copy of datasheet will be provided with the products, please refer to it for details.

Shipping

In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Alternative Names

env, Envelope glycoprotein gp160, Envelope glycoprotein gp160, Env polyprotein, Surface protein gp120, Glycoprotein 120, gp120, Transmembrane protein gp41, Glycoprotein 41, gp41

Data Image
  • SDS-PAGE
    SDS PAGE for recombinant HIV1 gp120 / SU
  • Bioactivity
    Detects Suvizumab in indirect ELISAs.
References

Hidden dUTPase sequence in human immunodeficiency virus type 1 gp120. PMID: 9847382

HIV-1 gp120 and immune network. PMID: 15370273

The alpha helix 1 from the first conserved region of HIV1 gp120 is reconstructed in the short NQ21 peptide. PMID: 29273432

The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development. PMID: 25163695

Entry inhibitors directed towards glycoprotein gp120: an overview on a promising target for HIV-1 therapy. PMID: 23278399

The SPL7013 dendrimer destabilizes the HIV-1 gp120-CD4 complex. PMID: 26495445

HIV gp120: double lock strategy foils host defences. PMID: 9739096

Mutational pressure makes HIV1 gp120 linear B-cell epitopes shorter and may lead to their disappearance. PMID: 20129670

Gp120 on HIV-1 Virions Lacks O-Linked Carbohydrate. PMID: 25915761

Plugging gp120s cavity. PMID: 19000812

Molecular mechanism of HIV-1 gp120 mutations that reduce CD4 binding affinity. PMID: 23297802

Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug. PMID: 21345545

Computational design, synthesis and evaluation of new sulphonamide derivatives targeting HIV-1 gp120. PMID: 31792886

NMR observation of HIV-1 gp120 conformational flexibility resulting from V3 truncation. PMID: 24819826

A modeled structure of an aptamer-gp120 complex provides insight into the mechanism of HIV-1 neutralization. PMID: 20527993

Variability in the Glycosylation Patterns of gp120 Proteins from Different Human Immunodeficiency Virus Type 1 Isolates Expressed in Different Host Cells. PMID: 34448591

The β20-β21 of gp120 is a regulatory switch for HIV-1 Env conformational transitions. PMID: 29051495

gp120: Biologic aspects of structural features. PMID: 11244037

Genetic variability of HIV-1. PMID: 8883605

[Structural mechanism of immune evasion of HIV-1 gp120 by genomic, computational, and experimental science]. PMID: 21972555

Allosteric induction of the CD4-bound conformation of HIV-1 Gp120. PMID: 24304511

Structure and Dynamics of the Native HIV-1 Env Trimer. PMID: 25762739

Potential drug targets on the HIV-1 envelope glycoproteins, gp120 and gp41. PMID: 12769725

The gp120 protein is a second determinant of decreased neurovirulence of Indian HIV-1C isolates compared to southern African HIV-1C isolates. PMID: 25188269

A non-canonical binding interface in the crystal structure of HIV-1 gp120 core in complex with CD4. PMID: 28429756

The HIV-1 gp120 major variable regions modulate cold inactivation. PMID: 23345516

Conformational characterization of aberrant disulfide-linked HIV-1 gp120 dimers secreted from overexpressing cells. PMID: 20471426

The V1/V2 loop of HIV-1 gp120 is necessary for Tat binding and consequent modulation of virus entry. PMID: 23916815

Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist. PMID: 24502450

Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. PMID: 11188697

Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. PMID: 20080564

Stoichiometric parameters of HIV-1 entry. PMID: 25463598

Insight derived from molecular dynamics simulations into molecular motions, thermodynamics and kinetics of HIV-1 gp120. PMID: 25105502

[Structure and function of oligosaccharide chains of the envelope glycoprotein gp120 of human immunodeficiency virus type 1]. PMID: 1518160

The V1V2 Region of HIV-1 gp120 Forms a Five-Stranded Beta Barrel. PMID: 26018158

Binding of HIV-1 gp120 glycoprotein to silica nanoparticles modified with CD4 glycoprotein and CD4 peptide fragments. PMID: 22117536

Local conformational stability of HIV-1 gp120 in unliganded and CD4-bound states as defined by amide hydrogen/deuterium exchange. PMID: 20660185

Conformation of gp120 determines the sensitivity of HIV-1 DH012 to the entry inhibitor IC9564. PMID: 15207637

Characterization of the secreted, native gp120 and gp160 of the human immunodeficiency virus type 1. PMID: 2187500

Correlated mutations at gp120 positions 322 and 440: implications for gp120 structure. PMID: 18275085

Morphometric analysis of envelope glycoprotein gp120 distribution on HIV-1 virions. PMID: 7678271

Nonneutralizing antibodies to the CD4-binding site on the gp120

Development of noninvasive imaging to measure spontaneous pain in mice., PMID:40475419

Retrospective analysis of sex-disaggregated immune responses to ALVAC-HIV and bivalent subtype C gp120/MF59 HIV vaccines., PMID:40438096

Immunoinformatic-driven design and evaluation of multi-epitope mRNA vaccine targeting HIV-1 gp120., PMID:40433366

Conformational trajectory of the HIV-1 fusion peptide during CD4-induced envelope opening., PMID:40382314

Distinct region-specific neutralization profiles of contemporary HIV-1 clade C against best-in-class broadly neutralizing antibodies., PMID:40377318

Convergence and divergence of B cell responses in two HIV-1 Env immunizations in Rhesus macaques., PMID:40374902

Vaccination of nonhuman primates elicits a broadly neutralizing antibody lineage targeting a quaternary epitope on the HIV-1 Env trimer., PMID:40339576

Neurovirulent and non-neurovirulent strains of HIV-1 and their Tat proteins induce differential cytokine-chemokine profiles., PMID:40313367

Neuroinflammation, Blood-Brain Barrier, and HIV Reservoirs in the CNS: An In-Depth Exploration of Latency Mechanisms and Emerging Therapeutic Strategies., PMID:40285014

Computationally Selected Multivalent HIV-1 Subtype C Vaccine Protects Against Heterologous SHIV Challenge., PMID:40266065

Comprehensive maps of escape mutations from antibodies 10-1074 and 3BNC117 for Envs from two divergent HIV strains., PMID:40261015

ALVAC-prime and monomeric gp120 protein boost induces distinct HIV-1 specific humoral and cellular responses compared with adenovirus-prime and trimeric gp140 protein boost., PMID:40215224

Safety, pharmacokinetics, and biological activity of CD4-mimetic BNM-III-170 in SHIV-infected rhesus macaques., PMID:40192306

Safety and implementation of phase I randomized GLA-SE-adjuvanted CH505TF gp120 HIV vaccine trial in newborns., PMID:40178906

Divalent HIV-1 gp120 Immunogen Exhibits Selective Avidity for Broadly Neutralizing Antibody VRC01 Precursors., PMID:40161655

A gp41 HR2 residue modulates the susceptibility of HIV-1 envelope glycoproteins to small molecule inhibitors targeting gp120., PMID:40145736

Covariation of Amino Acid Substitutions in the HIV-1 Envelope Glycoprotein gp120 and the Antisense Protein ASP Associated with Coreceptor Usage., PMID:40143251

Host factor Naf1 restricts HIV-1 infection of myeloid cells and compromises the capacity of dendritic cell to prime CD4+ T cell., PMID:40139499

The membrane-proximal external region of human immunodeficiency virus (HIV-1) envelope glycoprotein trimers in A18-lipid nanodiscs., PMID:40089599

[Quercetin mitigates HIV-1 gp120-induced rat astrocyte neurotoxicity via promoting G3BP1 disassembly in stress granules]., PMID:40031974

A Pentavalent HIV-1 Subtype C Vaccine Containing Computationally Selected gp120 Strains Improves the Breadth of V1V2 Region Responses., PMID:40006680

HIV-1 gp120 Interactions with Nicotine Modulate Mitochondrial Network Properties and Amyloid Release in Microglia., PMID:39992414

Versatile Features of an Antibody Mimetic Peptide and Its Variants., PMID:39962901

Isolation and structure elucidation of Dm-CVNH, a new cyanovirin-N homolog with activity against SARS-CoV-2 and HIV-1., PMID:39956341

NK cell depletion in bispecific antibody therapy is associated with lack of HIV control after ART interruption., PMID:39953264

Cysteines shape antibody battles for HIV-1 Env., PMID:39947129

Activation of CXCR3+ Tfh cells and B cells in lymph nodes during acute HIV-1 infection correlates with HIV-specific antibody development., PMID:39932316

PET imaging of HIV-1 envelope protein gp120 using 18F-labeled nanobodies., PMID:39917021

Conformational activation and disulfide exchange in HIV-1 Env induce cell-free lytic/fusogenic transformation and enhance infection., PMID:39912667

Rare twin cysteine residues in the HIV-1 envelope variable region 1 link to neutralization escape and breadth development., PMID:39909038

Covariation of amino acid substitutions in the HIV-1 envelope glycoprotein gp120 and the antisense protein ASP associated with coreceptor usage., PMID:39868319

Monovalent Lectin Microvirin Utilizes Hydropathic Recognition of HIV-1 Env for Inhibition of Virus Cell Infection., PMID:39861871

PKR Inhibitor C16 Regulates HIV-gp120 Induced Neuronal Injury and Cognitive Impairment in Vivo and in Vitro Models., PMID:39752056

p62 Binding to Protein Kinase C Regulates HIV-1 gp120 V3 Loop Induced Microglial Inflammation., PMID:39731677

Two Disaccharide-Bearing Polyethers, K-41B and K-41Bm, Potently Inhibit HIV-1 via Mechanisms Different from That of Their Precursor Polyether, K-41A., PMID:39727933

A multidonor class of highly glycan-dependent HIV-1 gp120-gp41 interface-targeting broadly neutralizing antibodies., PMID:39675002

HVTN 123: A Phase 1, Randomized Trial Comparing Safety and Immunogenicity of CH505TF gp120 Produced by Stably and Transiently Transfected Cell Lines., PMID:39671174

Stronger binding affinities of gp120/CD4 in Catarrhini provide insights into HIV/host interactions., PMID:39620069

Optimization of a Piperidine CD4-Mimetic Scaffold Sensitizing HIV-1 Infected Cells to Antibody-Dependent Cellular Cytotoxicity., PMID:39563795

Comparative Analysis of IMT-P8 and LDP12 Cell-Penetrating Peptides in Increasing Immunostimulatory Properties of HIV-1 Nef-MPER-V3 Antigen., PMID:39558498

Inducible cell lines producing replication-defective human immunodeficiency virus particles containing envelope glycoproteins stabilized in a pretriggered conformation., PMID:39508605

Type-1-to-type-2 transition of brain microvascular pericytes induced by cytokines and disease-associated proteins: Role in neuroinflammation and blood-brain barrier disruption., PMID:39473432

Potent broadly neutralizing antibodies mediate efficient antibody-dependent phagocytosis of HIV-infected cells., PMID:39466835

Investigating the Effect of GLU283 Protonation State on the Conformational Heterogeneity of CCR5 by Molecular Dynamics Simulations., PMID:39435878

Signal peptide exchange alters HIV-1 envelope antigenicity and immunogenicity., PMID:39380992

CD4 downregulation precedes Env expression and protects HIV-1-infected cells from ADCC mediated by non-neutralizing antibodies., PMID:39373535

Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses., PMID:39339842

Simultaneous Protein and RNA Analysis in Single Extracellular Vesicles, Including Viruses., PMID:39306763

AI-based IsAb2.0 for antibody design., PMID:39285513

Structural and Functional Dysregulation of the Brain Endothelium in HIV Infection and Substance Abuse., PMID:39272987

Datasheet
$ 480
Product specifications
100 μg 480 1 mg 2880

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Recombinant HIV1 gp120/SU Protein, C-His [EVV07801]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only